Skip to main content
Swing Capital

Strides Pharma Science Ltd

NSE: STAR BSE: 532531Pharma

Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2] The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.[3]

₹1,115
52W: ₹660 — ₹1231
PE 56 · Book ₹345 · +223% vs book
Market Cap₹10,274 Cr
Stock P/E56Price to Earnings
ROCE4.66%Return on Capital
ROE85.9%Return on Equity
Div. Yield0.36%Face Value ₹10

Strengths

  • +Company has reduced debt.
  • +Company has delivered good profit growth of 89.9% CAGR over last 5 years
  • +Company has a good return on equity (ROE) track record: 3 Years ROE 28.8%
  • +Company has been maintaining a healthy dividend payout of 114%

Weaknesses

  • −Stock is trading at 3.32 times its book value
  • −The company has delivered a poor sales growth of 4.81% over past five years.
  • −Tax rate seems low
  • −Promoters have pledged 27.3% of their holding.
  • −Earnings include an other income of Rs.131 Cr.
  • −Company has high debtors of 248 days.
  • −Working capital days have increased from 57.4 days to 82.8 days

Shareholding Pattern

Promoters27.91%
FIIs28.68%
DIIs14.44%
Public28.96%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters25.86%25.84%▼0.026.82%▲1.028.3%▲1.528.3%27.86%▼0.427.86%27.91%▲0.1
FIIs26.71%30.08%▲3.428.48%▼1.628.32%▼0.228.02%▼0.328.51%▲0.529.52%▲1.028.68%▼0.8
DIIs18.17%18.24%▲0.116.92%▼1.313.72%▼3.213.3%▼0.412.98%▼0.313.02%▲0.014.44%▲1.4
Public28.87%25.83%▼3.027.78%▲2.029.65%▲1.930.38%▲0.730.62%▲0.229.59%▼1.028.96%▼0.6

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales553380603586520551556499522554
Expenses514378492520464477488431460472
Operating Profit38111166557468676281
OPM %7%0%18%11%11%13%12%13%12%15%
Net Profit-705221715161332122
EPS ₹-0.75-0.045.650.261.881.621.751.453.4813.23

AI Insights

Revenue Trend

TTM revenue at ₹2,130Cr, down 0.4% YoY. OPM at 13%.

Debt Position

Borrowings at ₹1,255Cr. Debt-to-equity ratio: 0.41x. Healthy balance sheet.

Capex Cycle

CWIP at ₹102Cr (13% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 14.44% (-5.16pp change). FIIs: 28.68% (+11.96pp change). Promoters hold 27.91%.

Margin & Efficiency

ROCE declining from 11% (Mar 2014) to 5% (Mar 2025). Working capital days: 83.

Valuation

PE 56x with 4.66% ROCE. Price is 223% above book value of ₹345. Dividend yield: 0.36%.

Recent Announcements